What is Prostamax?
Prostamax is a short-chain tetrapeptide bioregulator with the amino acid sequence Lys-Glu-Asp-Pro (KEDP). It belongs to a class of compounds known as Khavinson peptides, a family of tissue-specific short peptides originally developed in Russia by Professor Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology. These bioregulators are designed to restore gene expression in specific tissues that have undergone age-related decline, and prostamax is the prostate-specific member of this family.
The proposed mechanism of action involves epigenetic modulation at the chromatin level. Research indicates that short peptide bioregulators in the Khavinson family can interact with DNA-histone complexes, influencing chromatin structural dynamics in ways that reactivate genes that have become transcriptionally silenced with aging. In prostate tissue specifically, this modulation is associated with restoration of normal epithelial cell proliferation rates, reduction in aberrant apoptosis, and normalization of protein expression patterns characteristic of younger tissue. Published studies have described prostamax exposure in cell models as producing a gene expression profile more consistent with younger prostatic tissue, with enhanced cellular proliferation and reduced pro-senescent signaling.
Animal and early clinical research has examined prostamax in the context of chronic prostatitis. A study published in the Open Journal of Urology investigated the use of prostamax in men with chronic aseptic prostatitis, finding that peptide treatment was associated with reduction in inflammatory markers including vessel hyperemia, cellular infiltration, and tissue edema in prostate biopsies. The research also noted potential for restraining the development of sclerotic and atrophic processes in the prostate gland, which are hallmarks of chronic inflammatory prostate disease and benign prostatic changes associated with aging.
It is important to contextualize the evidence base for prostamax appropriately. The available research is predominantly preclinical or from small, non-blinded clinical studies conducted in the Russian literature, which has not been consistently replicated in large-scale Western randomized controlled trials. Prostamax is not a treatment for prostate cancer. Its proposed role is in supporting prostate tissue health and reducing the functional consequences of chronic inflammation and aging, not in addressing malignant disease. The compound should be understood as a research-stage bioregulator with promising early signals but an evidence base that requires further rigorous investigation.
Research Supply
Source high-purity Prostamax for your research
Dosage Guide
Route: Intramuscular injection (preferred; superior bioavailability) or oral capsules
Dosing Schedule
| Period | Dose |
|---|---|
| Injectable cycle (daily) | 500 mcg to 1 mg intramuscularly per day for 10-20 days |
| Oral cycle (daily) | 10-20 mg orally once or twice daily with meals for 10-20 days |
Reconstitution
Injection Volumes
| Dose | Volume | Syringe Units |
|---|---|---|
| 500 mcg | Per supplier instructions | Intramuscular |
| 1 mg | Per supplier instructions | Intramuscular |
Cycling Protocol
10-20 days
3-6 months between cycles
Standard Khavinson peptide protocols suggest 2-4 cycles per year. Long-term continuous use protocols have not been formally evaluated.
Administration Tips
- Injectable form is considered to have superior bioavailability for tissue-specific effect
- Begin at 500 mcg injectable; increase to 1 mg based on tolerance
- Oral form: take with meals once or twice daily
- Standard Khavinson protocols suggest repeating cycles two to four times per year
- Allow 3 to 6 months between cycles for ongoing tissue maintenance
- Refrigerate reconstituted injectable solution; use within 14 to 30 days
Risks & Side Effects
Commonly Reported
Serious Risks
Hypersensitivity
Allergic reactions to peptide components are possible. Discontinue and seek medical attention if rash, urticaria, or breathing difficulty develops.
Unknown long-term safety profile
The published evidence base lacks multi-year randomized safety data in Western clinical trial formats. Long-term consequences of chronic epigenetic modulation in prostate tissue are not established.
Interactions with prostate medications
Men taking alpha-blockers, 5-alpha reductase inhibitors, or other prostate-targeted therapies should discuss use with a physician before adding prostamax.
Contraindications
- Known hypersensitivity to any component of the formulation
- Prostate cancer (prostamax is not indicated for malignant disease and has not been studied in this population)
- Pregnancy (not applicable by indication; listed for completeness)
- Use in combination with immunosuppressive therapy (theoretical concern given peptide's immune-modulatory effects in tissue models)
Frequently Asked Questions
Related Peptides
Experts Covering Prostamax
LEGAL DISCLAIMER
The information provided on this page is for educational and informational purposes only and is not intended as medical advice. Prostamax has not been approved by the FDA for any medical condition. The available evidence base is primarily preclinical or derived from small-scale clinical studies and has not been validated in large Western randomized controlled trials. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.